Camelid nanobodies: Killing two birds with one stone

Current Opinion in Structural Biology

Volumn 32, Issue , 2015, Pages 1-8

  Desmyter, Aline ^a,b   Spinelli, Silvia ^a,b   Roussel, Alain ^a,b   Cambillau, Christian ^a,b  

^a Centre National de la Recherche Scientifique   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CHEMOKINE RECEPTOR CXCR4; COMPLEMENTARY DNA; EPITOPE; MUSCARINIC M2 RECEPTOR; NANOBODY; NEF PROTEIN; P21 ACTIVATED KINASE 2; PROTEIN;

BINDING AFFINITY; BIOTECHNOLOGY; CHEMOTAXIS; COMPLEMENTARITY DETERMINING REGION; CRYSTALLIZATION; CYTOPLASM; DROMEDARY; ELECTRON MICROSCOPY; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; LAMA GLAMA; NONHUMAN; PROTEIN TARGETING; REVIEW; SACCHAROMYCES CEREVISIAE; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; NEW WORLD CAMELID; PROCEDURES; PROTEIN CONFORMATION; PROTEIN STABILITY;

AVES; CAMELIDAE;

ANIMALS; CAMELIDS, NEW WORLD; CRYSTALLIZATION; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEINS; SINGLE-DOMAIN ANTIBODIES;

EID: 84921418700     PISSN: 0959440X     EISSN: 1879033X     Source Type: Journal    
DOI: 10.1016/j.sbi.2015.01.001     Document Type: Review

References (49)

1. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Bendahman N., Hamers R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
2. Desmyter A., Transue T.R., Ghahroudi M.A., Thi M.H.D., Poortmans F., Hamers R., Muyldermans S., Wyns L. Crystal structure of a camel single-domain V-H antibody fragment in complex with lysozyme. Nat Struct Biol 1996, 3:803-811.
3. Spinelli S., Frenken L., Bourgeois D., deRon L., Bos W., Verrips T., Anguille C., Cambillau C., Tegoni M. The crystal structure of a llama heavy chain variable domain. Nat Struct Biol 1996, 3:752-757.
4. Muyldermans S., Cambillau C., Wyns L. Recognition of antigens by single domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem Sci 2001, 26:230-235.
5. Spinelli S., Tegoni M., Frenken L., van Vliet C., Cambillau C. Lateral recognition of a dye hapten by a llama VHH domain. J Mol Biol 2001, 311:123-129.
6. Desmyter A., Spinelli S., Payan F., Lauwereys M., Wyns L., Muyldermans S., Cambillau C. Three Camelid VHH domains in complex with porcine pancreatic alpha-amylase - inhibition and versatility of binding topology. J Biol Chem 2002, 277:23645-23650.
7. Lauwereys M., Ghahroudi M.A., Desmyter A., Kinne J., Holzer W., De Genst E., Wyns L., Muyldermans S. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J 1998, 17:3512-3520.
8. Pardon E., Laeremans T., Triest S., Rasmussen S.G.F., Wohlkonig A., Ruf A., Muyldermans S., Hol W.G.J., Kobilka B.K., Steyaert J. A general protocol for the generation of Nanobodies for structural biology. Nat Protocols 2014, 9:674-693.
9. Muyldermans S. Nanobodies natural single-domain antibodies. Annu Rev Biochem 2013, 82:775-797.
10. Verheesen P., Roussis A., de Haard H.J., Groot A.J., Stam J.C., den Dunnen J.T., Frants R.R., Verkleij A.J., Verrips C.T., van der Maarel S.M. Reliable and controllable antibody fragment selections from Camelid non-immune libraries for target validation. Biochim Biophys Acta-Proteins Proteomics 2006, 1764:1307-1319.
11. Olichon A., de Marco A. Preparation of a naive library of camelid single domain antibodies. Methods Mol Biol 2012, 911:65-78.
12. Monegal A., Ami D., Martinelli C., Huang H., Aliprandi M., Capasso P., Francavilla C., Ossolengo G., de Marco A. Immunological applications of single-domain llama recombinant antibodies isolated from a naive library. Protein Eng Des Sel 2009, 22:273-280.
13. van der Linden R.H.J., de Geus B., Frenken L.G.J., Peters H., Verrips C.T. Improved production and function of llama heavy chain antibody fragments by molecular evolution. J. Biotechnol. 2000, 80:261-270.
14. Djender S., Schneider A., Beugnet A., Crepin R., Desrumeaux K., Romani C., Moutel S., Perez F., de Marco A. Bacterial cytoplasm as an effective cell compartment for producing functional VHH-based affinity reagents and Camelidae IgG-like recombinant antibodies. Microb Cell Fact 2014, 13:140.
15. de Marco A. Co-expression and co-purification of antigen-antibody complexes in bacterial cytoplasm and periplasm. Methods Mol Biol 2014, 1129:125-135.
16. Thomassen Y.E., Verkleij A.J., Boonstra J., Verrips C.T. Specific production rate of VHH antibody fragments by Saccharomyces cerevisiae is correlated with growth rate, independent of nutrient limitation. J Biotechnol 2005, 118:270-277.
17. Emmerson C.D., van der Vlist E.J., Braam M.R., Vanlandschoot P., Merchiers P., de Haard H.J.W., Verrips C.T., Henegouwen P., Dolk E. Enhancement of polymeric immunoglobulin receptor transcytosis by biparatopic VHH. PLoS ONE 2011,6.
18. Jahnichen S., Blanchetot C., Maussang D., Gonzalez-Pajuelo M., Chow K.Y., Bosch L., De Vrieze S., Serruys B., Ulrichts H., Vandevelde W., et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A 2010, 107:20565-20570.
19. Klooster R., Maassen B.T.H., Stam J.C., Hermans P.W., ten Haaft M.R., Detmers F.J.M., de Haard H.J., Post J.A., Verrips C.T. Improved anti-IgG and HSA affinity ligands: clinical application of VHH antibody technology. J Immunol Methods 2007, 324:1-12.
20. Szynol A., de Soet J.J., Sieben-van Tuyl E., Bos J.W., Frenken L.G. Bactericidal effects of a fusion protein of llama heavy-chain antibodies coupled to glucose oxidase on oral bacteria. Antimicrob Agents Chemotherapy 2004, 48:3390-3395.
21. Lulf S., Matz J., Rouyez M.C., Jarviluoma A., Saksela K., Benichou S., Geyer M. Structural basis for the inhibition of HIV-1 Nef by a high-affinity binding single-domain antibody. Retrovirology 2014, 11:24.
22. Hassaine G., Deluz C., Grasso L., Wyss R., Tol M.B., Hovius R., Graff A., Stahlberg H., Tomizaki T., Desmyter A., et al. X-ray structure of the mouse serotonin 5-HT3 receptor. Nature 2014, 512:276-281.
23. Desmyter A., Farenc C., Mahony J., Spinelli S., Bebeacua C., Blangy S., Veesler D., van Sinderen D., Cambillau C. Viral infection modulation and neutralization by camelid nanobodies. Proc Natl Acad Sci U S A 2013, 110:E1371-E1379.
24. Ring A.M., Manglik A., Kruse A.C., Enos M.D., Weis W.I., Garcia K.C., Kobilka B.K. Adrenaline-activated structure of beta(2)-adrenoceptor stabilized by an engineered nanobody. Nature 2013, 502:575-580.
25. Schmitz K.R., Bagchi A., Roovers R.C., Henegouwen P., Ferguson K.M. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Structure 2013, 21:1214-1224.
26. Sosa B.A., Demircioglu F.E., Chen J.Z., Ingram J., Ploegh H.L., Schwartz T.U. How lamina-associated polypeptide 1 (LAP1) activates Torsin. Elife 2014, 3:e03239.
27. Oyen D., Wechselberger R., Srinivasan V., Steyaert J., Barlow J.N. Mechanistic analysis of allosteric and non-allosteric effects arising from nanobody binding to two epitopes of the dihydrofolate reductase of Escherichia coli. Biochim Biophys Acta 2013, 1834:2147-2157.
28. Rudolph M.J., Vance D.J., Cheung J., Franklin M.C., Burshteyn F., Cassidy M.S., Gary E.N., Herrera C., Shoemaker C.B., Mantis N.J. Crystal structures of ricin toxin's enzymatic subunit (RTA) in complex with neutralizing and non-neutralizing single-chain antibodies. J Mol Biol 2014, 426:3057-3068.
29. Murase T., Eugenio L., Schorr M., Hussack G., Tanha J., Kitova E.N., Klassen J.S., Ng K.K.S. Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile. J Biol Chem 2014, 289:2331-2343.
30. De Genst E., Chan P.H., Pardon E., Hsu S.T.D., Kumita J.R., Christodoulou J., Menzer L., Chirgadze D.Y., Robinson C.V., Muyldermans S., et al. A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formation. J Phys Chem B 2013, 117:13245-13258.
31. Vanderhaegen S., Fislage M., Domanska K., Versees W., Pardon E., Bellotti V., Steyaert J. Structure of an early native-like intermediate of beta 2-microglobulin amyloidogenesis. Protein Sci 2013, 22:1349-1357.
32. Chaikuad A., Keates T., Vincke C., Kaufholz M., Zenn M., Zimmermann B., Gutierrez C., Zhang R.G., Hatzos-Skintges C., Joachimiak A., et al. Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies. Biochem J 2014, 459:59-69.
33. Lo A.W., Moonens K., De Kerpel M., Brys L., Pardon E., Remaut H., De Greve H. The molecular mechanism of Shiga toxin Stx2e neutralization by a single-domain antibody targeting the cell receptor-binding domain. J Biol Chem 2014, 289:25374-25381.
34. Acharya P., Luongo T.S., Georgiev I.S., Matz J., Schmidt S.D., Louder M.K., Kessler P., Yang Y.P., McKee K., O'Dell S., et al. Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites. J Virol 2013, 87:10173-10181.
35. Ward A.B., Szewczyk P., Grimard V., Lee C.W., Martinez L., Doshi R., Caya A., Villaluz M., Pardon E., Cregger C., et al. Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc Natl Acad Sci U S A 2013, 110:13386-13391.
36. Pathare G.R., Nagy I., Sledz P., Anderson D.J., Zhou H.J., Pardon E., Steyaert J., Forster F., Bracher A., Baumeister W. Crystal structure of the proteasomal deubiquitylation module Rpn8-Rpn11. Proc Natl Acad Sci U S A 2014, 111:2984-2989.
37. Ehrnstorfer I.A., Geertsma E.R., Pardon E., Steyaert J., Dutzler R. Crystal structure of a SLC11 (NRAMP) transporter reveals the basis for transition-metal ion transport. Nat Struct Mol Biol 2014, 21:990-996.
38. Abskharon R.N.N., Giachin G., Wohlkonig A., Soror S.H., Pardon E., Legname G., Steyaert J. Probing the N-terminal beta-sheet conversion in the crystal structure of the human prion protein bound to a nanobody. J Am Chem Soc 2014, 136:937-944.
39. Bethuyne J., De Gieter S., Zwaenepoel O., Garcia-Pino A., Durinck K., Verhelle A., Hassanzadeh-Ghassabeh G., Speleman F., Loris R., Gettemans J. A nanobody modulates the p53 transcriptional program without perturbing its functional architecture. Nucleic Acids Res 2014, 10.1093/nar/gku962.
40. Kruse A.C., Ring A.M., Manglik A., Hu J.X., Hu K., Eitel K., Hubner H., Pardon E., Valant C., Sexton P.M., et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 2013, 504:101-110.
41. Lam A.Y., Pardon E., Korotkov K.V., Hol W.G.J., Steyaert J. Nanobody-aided structure determination of the EpsI:EpsJ pseudopilin heterodimer from Vibrio vulnificus. J Struct Biol 2009, 166:8-15.
42. Khamrui S., Turley S., Pardon E., Steyaert J., Fan E.K., Verlinde C., Bergman L.W., Hol W.G.J. The structure of the D3 domain of Plasmodium falciparum myosin tail interacting protein MTIP in complex with a nanobody. Mol Biochem Parasitol 2013, 190:87-91.
43. De Haard H.J.W., Bezemer S., Ledeboer A.M., Muller W.H., Boender P.J., Moineau S., Coppelmans M.C., Verkleij A.J., Frenken L.G.J., Verrips C.T. Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection. J Bacteriol 2005, 187:4531-4541.
44. Sciara G., Bebeacua C., Bron P., Tremblay D., Ortiz-Lombardia M., Lichiere J., van Heel M., Campanacci V., Moineau S., Cambillau C. Structure of lactococcal phage p2 baseplate and its mechanism of activation. Proc Natl Acad Sci U S A 2010, 107:6852-6857.
45. Veesler D., Spinelli S., Mahony J., Lichiere J., Blangy S., Bricogne G., Legrand P., Ortiz-Lombardia M., Campanacci V., van Sinderen D., et al. Structure of the phage TP901-1 1.8 MDa baseplate suggests an alternative host adhesion mechanism. Proc Natl Acad Sci U S A 2012, 109:8954-8958.
46. Steyaert J., Kobilka B.K. Nanobody stabilization of G protein-coupled receptor conformational states. Curr Opin Struct Biol 2011, 21:567-572.
47. Rasmussen S.G.F., Choi H.J., Fung J.J., Pardon E., Casarosa P., Chae P.S., DeVree B.T., Rosenbaum D.M., Thian F.S., Kobilka T.S., et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 2011, 469:175-180.
48. Rasmussen S.G., DeVree B.T., Zou Y., Kruse A.C., Chung K.Y., Kobilka T.S., Thian F.S., Chae P.S., Pardon E., Calinski D., et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 2011, 477:549-555.
49. Doshi R., Chen B.R., Vibat C.R., Huang N., Lee C.W., Chang G. In vitro nanobody discovery for integral membrane protein targets. Sci Rep 2014, 4:6760.